Department of Oncology and Haematology, ABC Foundation School of Medicine, Av. Príncipe de Gales, n. 821, anexo 3, Santo André/SP, 09060-650, Brazil.
Ther Adv Med Oncol. 2012 Jul;4(4):167-72. doi: 10.1177/1758834012441049.
The objective of this study was to evaluate the safety of using tegafur-uracil (UFT) in colorectal cancer patients with partial dihydropyrimidine dehydrogenase (DPD) deficiency.
The study included five colorectal cancer patients who presented with acute toxicity (grades 3 and 4) after being given the first cycle of chemotherapy using 5-fluorouracil. The DPD deficiency was confirmed by gene sequencing. After a full recovery from all side effects, we changed the regimen to UFT (300 mg/m(2)/day) associated with leucovorin (90 mg/day) for 21 days, with an empirical dose reduction of at least 10% in the first cycle.
We prospectively analysed 22 UFT cycles in 5 patients. We did not observe any episodes of grade 3 or 4 toxicity. The predominant toxicities were of grades 1 and 2 (nausea, vomiting and diarrhoea).
Here, we demonstrate a complete absence of severe toxicity in all patients and cycles analysed. We believe that UFT is a safe alternative for the treatment of patients with partial DPD deficiency.
本研究旨在评估在部分二氢嘧啶脱氢酶（DPD）缺乏的结直肠癌患者中使用替加氟-尿嘧啶（UFT）的安全性。
本研究纳入了 5 名结直肠癌患者，他们在接受首个氟尿嘧啶化疗周期后出现急性毒性（3 级和 4 级）。DPD 缺乏通过基因测序得到确认。在所有副作用完全恢复后，我们将方案改为 UFT（300mg/m2/天）联合亚叶酸（90mg/天），第 1 周期经验性剂量减少至少 10%。
我们前瞻性分析了 5 名患者的 22 个 UFT 周期。我们未观察到任何 3 级或 4 级毒性事件。主要毒性为 1 级和 2 级（恶心、呕吐和腹泻）。
本研究中，我们证明了所有患者和分析周期均无严重毒性。我们认为 UFT 是治疗部分 DPD 缺乏患者的一种安全替代方案。
